Mozavaptan

Mozavaptan
Clinical data
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name N-[4-(5-Dimethylamino-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]-2-methylbenzamide;
CAS Number	137975-06-5 ;
PubChem CID	119369;
IUPHAR/BPS	2197;
ChemSpider	106618 ;
UNII	17OJ42922Y;
ChEMBL	ChEMBL420762 ;
CompTox Dashboard (EPA)	DTXSID8057641 ;
Chemical and physical data
Formula	C27H29N3O2
Molar mass	427.548 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cc1ccccc1C(=O)Nc2ccc(cc2)C(=O)N3c4ccccc4C(CCC3)N(C)C;
	InChI InChI=1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31) ; Key:WRNXUQJJCIZICJ-UHFFFAOYSA-N ;
	(what is this?) (verify)

Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.

References

Spreitzer H (November 20, 2006). "Neue Wirkstoffe - Conivaptan". Österreichische Apothekerzeitung (in German) (24/2006).
"Conivaptan hydrochloride". Molecule of the Month. Prous Science. November 2006.

This antihypertensive-related article is a stub. You can help Wikipedia by expanding it.